Manufacturing and banking of mesenchymal stem cells

Sreedhar Thirumala, W. Scott Goebel, Erik J. Woods

Research output: Contribution to journalReview article

55 Scopus citations

Abstract

Introduction: Mesenchymal stem cells (MSC) and MSC-like cells hold great promise and offer many advantages for developing effective cellular therapeutics. Current trends indicate that the clinical application of MSC will continue to increase markedly. For clinical applications, large numbers of MSC are usually required, ideally in an off-the-shelf format, thus requiring extensive MSC expansion ex vivo and subsequent cryopreservation and banking. Areas covered: To exploit the full potential of MSC for cell-based therapies requires overcoming significant cell-manufacturing, banking and regulatory challenges. The current review will focus on the identification of optimal cell source for MSC, the techniques for production scale-up, cryopreservation and banking and the regulatory challenges involved. Expert opinion: There has been considerable success manufacturing and cryopreserving MSC at laboratory scale. Surprisingly little attention, however, has been given to translate these technologies to an industrial scale. The development of cost-effective advanced technologies for producing and cryopreserving commercial-scale MSC is important for successful clinical cell therapy.

Original languageEnglish (US)
Pages (from-to)673-691
Number of pages19
JournalExpert Opinion on Biological Therapy
Volume13
Issue number5
DOIs
StatePublished - May 1 2013

    Fingerprint

Keywords

  • Banking
  • Bioprocess
  • Bioreactor
  • Cell therapy
  • Controlled rate freezer
  • Cryopreservation
  • Cryoprotective agents
  • Current good manufacturing practice
  • DMSO
  • Fetal bovine serum
  • Mesenchymal stem cells

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Biochemistry
  • Drug Discovery

Cite this